An eight-week regimen of Gilead Sciences’ Harvoni (ledipasvir/sofosbuvir) plus its investigational vedroprevir boasted a near-perfect cure rate among those with genotype 1 and advanced liver disease, Medpage Today reports. Researchers conducted a single-center, open-label study of Harvoni plus the NS3/4A protease inhibitor vedroprevir, with or without ribavirin, among 46 people who had previously failed treatment with interferon and ribavirin.

Findings were presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco.

The participants were randomized to receive Harvoni and vedroprevir either with or without ribavirin.

Ninety-six percent of those who did not take ribavirin achieved a sustained virologic response 12 weeks after completing therapy (SVR12, considered a cure). Just 88 percent of those who took ribavirin were cured.

There were no serious adverse side effects among the participants. No one stopped treatment because of side effects. The side effects that did occur were generally mild; the most frequent were headache, rash and sinusitis.

To read the MedPage Today article, click here.